Agitation and Psychosis in Dementia

American Journal of Geriatric Psychiatry

Volumn 15, Issue 11, 2007, Pages 913-917

  Ballard, Clive ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; CITALOPRAM; DROPERIDOL; MEMANTINE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; THIORIDAZINE; TRIFLUOPERAZINE; VALPROIC ACID; ANTICONVULSIVE AGENT;

AGGRESSION; AGITATED DEPRESSION; AGITATION; ALZHEIMER DISEASE; AROMATHERAPY; BEHAVIOR DISORDER; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DELIRIUM; DELUSION; DEMENTIA; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; EVIDENCE BASED PRACTICE; EXTRAPYRAMIDAL SYNDROME; FALLING; GAIT DISORDER; HALLUCINATION; HUMAN; INCIDENCE; LONG TERM CARE; MENTAL HEALTH; MENTAL HEALTH CENTER; MOOD DISORDER; MORTALITY; PERIPHERAL EDEMA; PSYCHOSIS; QT PROLONGATION; RESPIRATORY TRACT INFECTION; SEDATION; SIDE EFFECT; STROKE; SYMPTOM; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; URINARY TRACT INFECTION; AGED; CHEMICALLY INDUCED DISORDER; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; RISK FACTOR; STATISTICS;

AGED; ALZHEIMER DISEASE; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; AROMATHERAPY; CEREBROVASCULAR DISORDERS; DEMENTIA; HUMANS; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 38449103010     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1097/JGP.0b013e3181584268     Document Type: Editorial

References (29)

1. Ballard C, Howard R: Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci 2006; 7:492-500
2. Schneider LS, Pollock VE, lyness SA: A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Cieriatr Soc 1990; 38:553-563
3. Lonergan E, Luxenberg J, Colford J, et al: Haloperidol for agitation in dementia. Cochrane Database Systematic Reviews 2005 ;4.
4. Schneider LS, Dagerman K, Insel PS: Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006; 14:191-210
5. Jeste D, Blazer D, Casey D, et al: ACNP white paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology (in press)
6. Schneider LS, Tariot PN, Dagerman KS, et al: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006; 355:1525-1538
7. Mintzer JE, Tune LE, Breder CD, et al: Arlpiprazole for the treatment of psychosis in institutionalized patients with Alzheimer's dementia: a multi-center, randomized, double blind, placebo controlled assessment of 3 fixed doses. AmJ Geriatr Psychiatry 2007; 15:918-931
8. Ballard C, Margallo-Lana M, Juszczak E, et al: Quetiapine and rlvastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 2005; 330: 874
9. Cohen-Mansfield J, Lipson S, Werner P, et al: Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study. Arch Intern Med 1999; 159:17331740
10. Bridges-Parlet S, Knopman D, Steffes S: Withdrawal of neuroleptic medications from institutionalised dementia patients, results of a double-blind baseline-treatment-controlled pilot study. J Geriatr Psychiatry Neurol 1997; 10:119-126
11. Ballard CG, Thomas A, Fossey J, et al: A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatrie inventory median cutoff is a predictor of clinical outcome. J Clin Psychiatry 2004; 65:114119
12. Tune LE, Steele C, Cooper T: Neuroleptic drugs in the management of behavioral symptoms of Alzheimer's disease. Psychiatr Clin North Am 1991; 14:353-373
13. ReillyJG, Ayis SA, Ferrler IN, et al: QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355:1048-1052
14. Committee for the Safety of Medicines: Atypical antipsychotic drugs and stroke. Available at: www.mhra.gov.uk/home/idcplg IdcService=SS-GET-PAGE&use Secondary=true&ss DocName= CON1004298&ss TargetNodeId=221
15. Gill SS, Rochon PA, Herrmann N, et al: Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005; 330:445
16. Herrmann N, Mamdani M, Lanctot KL: Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004; 161:1113-1115
17. U.S. Food and Drug Administration, FDA Public Health Advisory: Deaths with antipsychotics in elderly patients with behavioral disturbances. Location, Centre for Drug Evaluation and Research, 13, 2005. Available at: www.accessdata.fda.gov/scrlpts/cdrh/ cfdoes/psn/printer.cfm?id=330
18. Schneider LS, Dagerman KS, Insel P, et al: Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294:19341943
19. Wang PS, Schneewelss S, Avorn J, et al: Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005; 353:2335-2341
20. Hollis J, Grayson D, Forrester L, et al: Antipsychotic medication dispensing and risk of death in veterans and war widows 65 years and older. Am J Geriatr Psychiatry 2006; 40:981-986
21. Fossey J, Ballard C, Juszczak E, et al: Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ 2006; 332:756761
22. Ballard CG, O'Brien JT, Relchelt K, et al: Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa. J Clin Psychiatry 2002; 63:553-558
23. Holmes C, Wilkinson D, Dean C, et al: The efficacy of donepezil in the treatment of neuropsychiatrie symptoms in Alzheimer disease. Neurology 2004; 63:214-219
24. Gauthier S, Wirth Y, Mobius HJ: Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatrie Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry 2005; 20:459-464
25. Tariot PN, Erb R, Podgorskl CA, et al: Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155:54-61
26. Nyth AL, Gottfries CG: The clinical efficacy of Citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. BrJ Psychiatry 1990; 157:894-901
27. Pollock BG, Mulsant BH, Rosen J, et al: Comparison of Citalopram, perphenazine and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. AmJ Psychiatry 2002; 159:460-465
28. Pollock BG, Mulsant BH, Rosen J, et al: A double blind comparison of Citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry 2007; 15:942-952
29. Tinklenberg JR, Kraemer HC, Yafife K, et al: Donepezil treatment and Alzheimer disease: can we apply the results of randomized clinical trials in AD patients to clinical practice? Am J Geriatr Psychiatry 2007; 15:953-960